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AbsTrACT
Objective Up to 50% of patients with hypertrophic 
cardiomyopathy (hcM) show no disease- causing variants in 
genetic studies. TRIM63 has been suggested as a candidate 
gene for the development of cardiomyopathies, although 
evidence for a causative role in hcM is limited. We sought 
to investigate the relationship between rare variants in 
TRIM63 and the development of hcM.
Methods TRIM63 was sequenced by next generation 
sequencing in 4867 index cases with a clinical 
diagnosis of hcM and in 3628 probands with other 
cardiomyopathies. additionally, 3136 index cases 
with familial cardiovascular diseases other than 
cardiomyopathy (mainly channelopathies and aortic 
diseases) were used as controls.
results sixteen index cases with rare homozygous or 
compound heterozygous variants in TRIM63 (15 hcM 
and one restrictive cardiomyopathy) were included. no 
homozygous or compound heterozygous were identified 
in the control population. Familial evaluation showed 
that only homozygous and compound heterozygous 
had signs of disease, whereas all heterozygous family 
members were healthy. The mean age at diagnosis 
was 35 years (range 15–69). Fifty per cent of patients 
had concentric left ventricular hypertrophy (lVh) and 
45% were asymptomatic at the moment of the first 
examination. significant degrees of late gadolinium 
enhancement were detected in 80% of affected 
individuals, and 20% of patients had left ventricular (lV) 
systolic dysfunction. Fifty per cent had non- sustained 
ventricular tachycardia. Twenty per cent of patients 
suffered an adverse cerebrovascular event (20%).
Conclusion TRIM63 appears to be an uncommon cause 
of hcM inherited in an autosomal- recessive manner and 
associated with concentric lVh and a high rate of lV 
dysfunction.
InTrOduCTIOn
Hypertrophic cardiomyopathy (HCM) is the 
most common inherited cardiac disorder, with an 
estimated prevalence of at least 1:500.1 The under-
standing of the genetic architecture of HCM has 
greatly improved since the advent of next genera-
tion sequencing, but approximately 50% of cases 
remain unresolved.2 3
TRIM63 encodes an E3 ubiquitin- protein ligase 
known as muscle- specific RING- finger protein 1 
(MuRF1), which belongs to a family of proteins 
with RING zinc- finger motifs. It mainly localises 
to the Z- disk and M- line of the sarcomere, where 
it interacts with several sarcomeric proteins.4 5 
MuRF1 participates in the regulation of sarcomeric 
protein degradation through a process known as 
ubiquitination and plays an important role in linking 
myofibril components with intermediate filaments 
and microtubules.6 TRIM63 expression is upregu-
lated by atrophic stimuli,4 and TRIM63 knockout 
mice models exhibit an exaggerated hypertrophic 
response to stress and an increase in hypertrophy 
biomarkers.7 8
Genetic variants in TRIM63 were first suggested 
as a possible cause of HCM following the identifi-
cation of two heterozygous missense variants and 
a heterozygous nonsense variant, p.(Gln247*), in 
patients but not in controls.8 However, subsequent 
data on p.(Gln247*) showed that this variant is 
relatively common in the European population, and 
the relationship between TRIM63 and the develop-
ment of HCM has not been confirmed yet.9 10 Some 
authors have suggested that variants in TRIM63 
might act as modifiers of cardiac hypertrophy in 
the presence of a sarcomere pathogenic variant.11
On the basis of its potential role in cardiovas-
cular diseases, we sought to determine the role of 
TRIM63 as a candidate gene for the development 
of cardiomyopathies in a large cohort of patients 
referred for clinical genetic testing.
MeTHOds
From March 2013 to January 2019, TRIM63 was 
sequenced as a candidate gene using next- generation 
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sequencing in 4867 index cases with a clinical diagnosis of HCM 
and in 3628 probands with other cardiomyopathies referred to 
our centre for molecular genetic diagnosis. Additionally, 3136 
index cases with familial cardiovascular diseases other than 
cardiomyopathies (mainly channelopathies and aortic diseases) 
were used as controls. The phenotypes had been established by 
the referring centres prior to the genetic study. Patient samples 
were mainly received from hospitals in Spain and the UK, and 
the predominant ethnicity was European (>90%). The frequen-
cies of variants in the general population were determined by 
using the gnomAD database (http:// gnomad. broadinstitute. org; 
V.2.1.1, December 2019). According to gnomAD, the constraint 
score (observed/expected number of variants) for missense and 
loss- of- function (LoF) variants in TRIM63 suggests that this gene 
is tolerant to the aforementioned genetic changes. However, 
the variants reported in gnomAD are mainly found in hetero-
zygosity. To investigate the role of non- synonymous TRIM63 
(NM_032588.3) variants in homozygosity or compound hetero-
zygosity, probands harbouring rare variants (defined as those 
with minor allele frequency (MAF)<0.001) in homozygous 
or compound heterozygous state were analysed and invited to 
participate in segregation studies. Clinical and genetic familial 
cascade screening was performed when possible. In cases where 
a second pathogenic variant in a sarcomeric gene was identified, 
the latter variant was also included in family screening to deter-
mine the role of each of the identified variants in the familial 
phenotype. Finally, the clinical characteristics and outcomes of 
homozygous and compound heterozygous individuals (including 
probands and relatives) were assessed. Our study was conducted 
in accordance with the Declaration of Helsinki. Written consent 
was obtained from all participants.
Patient involvement
Patients were not involved in the design of this study. The index 
cases actively participated in the recruitment of first- degree 
relatives. They were central to the dissemination of the baseline 
information and our hypothesis, which helped to motivate the 
involvement of their families. All index cases received informa-
tion on the basis of genetic inheritance in order to adequately 
inform their relatives prior to contacting the research team. 
Once our study is published, we aim to disseminate the main 
results to all trial participants.
Genetic studies, variant filtering and variant classification
Coding exons and intronic boundaries of 219 genes related 
to inherited cardiovascular diseases and sudden cardiac death 
(online supplementary table 1) were captured using a custom 
probe library (SureSelect Target Enrichment Kit for Illumina 
paired- end multiplexed sequencing method; Agilent Technolo-
gies, Santa Clara, California, USA) and sequenced on the HiSeq 
1500 platform (Illumina, San Diego, California, USA) following 
Illumina protocols. The read depth (number of times that a base 
was sequenced by independent reads) of every nucleotide of 
genes related to the referred phenotype (including TRIM63) was 
>30 (mean 250–400). Exons that did not fulfil this standard 
were complementary sequenced using the Sanger method. Only 
likely protein- altering variants (missense, in- frame insertions/
deletions, frameshifts, nonsense and consensus splice- site vari-
ants) in the TRIM63 gene were analysed. Bioinformatic analysis 
was performed by means of a custom pipeline including software 
for variant calling, genotyping and annotation. To determine the 
pathogenicity of the identified variants, the American College of 
Medical Genetics and Genomics recommendations were used.12
statistical analysis
Continuous variables were expressed as mean±SD, and compar-
ison between groups was performed using the Student’s t test 
or the Mann- Whitney U test according to values distribution. 
Non- continuous variables were expressed as an integer number 
(per cent of total) and compared using the χ² test or Fisher’s 
exact test, as appropriate. A two- sided p<0.05 was considered 
to indicate statistical significance.
Analysis was performed using the R V.3.4.3 (The R Founda-
tion for Statistical Computing Platform).
LOd score (Logarithms of Odds) calculation
We calculated two- point LOD score for informative families by 
using the PARAMLINK package for R software. The model was 
set for a recessive inheritance pattern, with θ=0, phenocopy 
rate=0.005 and a penetrance of 0.95 for homozygous carriers. 
An indeterminate status was assigned to family members with a 
confounding cardiac diagnosis, as well as to individuals younger 
than 40 years who did not meet clinical criteria for HCM and 
could develop the disease afterwards.
resuLTs
A total of 20 (0.39%) index cases harbouring homozygous or 
compound heterozygous rare variants in TRIM63 were identi-
fied, all of them of European descent (non- Finnish). Nineteen 
had a clinical diagnosis of HCM and one was diagnosed with 
restrictive cardiomyopathy (RCM). No individuals with biallelic 
variants were identified in the disease controls. Likewise, in the 
gnomAD database, no homozygous individuals harbouring rare 
variants (MAF<0.001) are identified.
Fifteen of the homozygous/compound heterozygous 
patients with a clinical diagnosis of HCM and the patient 
with restrictive cardiomyopathy accepted to participate in this 
study. Five missense and three protein- truncating variants in 
TRIM63 (two frameshifts and one nonsense) were identified 
in these families. All the identified variants are present in the 
gnomAD database, with a low frequency (MAF<0.001) and 
only in heterozygosity, except for the p.(Leu37Val) and p.(Lys-
146Thrfs*24) variants, which are absent in this database. The 
identified variants, their frequency in gnomAD, the result of 
the bioinformatic predictors, their classification in ClinVar 
(whenever present) and their significance according to the 
ACMG recommendations can be found in online supplemen-
tary table 2. Only one HCM individual harbouring a homozy-
gous truncating variant in TRIM63 also carried a pathogenic 
truncating variant in a sarcomeric gene (MYBPC3), whereas in 
the rest of the included individuals, no other variants associ-
ated with the phenotype were identified.
Familial cosegregation
Twelve of the included families accepted further clinical and 
genetic screening as part of the evaluation. Three other fami-
lies accepted to undergo only clinical evaluation, and in one 
homozygous index case, family study was not possible. Clinical 
and genetic data on all evaluated family members as well as the 
family pedigrees are available online (online supplementary table 
S3 and figure S1).
After familial evaluation, three more homozygous and one 
compound heterozygous individuals were identified. Two of 
these met current diagnostic criteria for HCM,13 whereas the 
remaining two were considered likely to be affected, manifesting 
early signs of the disease given the grossly abnormal ECG, even 
though the left ventricular (LV) wall thickness did not fulfil the 
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Figure 1 Left ventricular maximal wall thickness according to zygosity. Left ventricular maximal wall thickness is higher in homozygous/compound 
heterozygous patients than in their heterozygous (p<0.001) or wild- type (p<0.001) family members. No statistically significant differences are 
observed between wild- type and heterozygous individuals.
classical criteria for HCM (ECGs available as online supplemen-
tary figure 2). None of the heterozygous or wild- type family 
members showed signs of the disease. Figure 1 shows the differ-
ence in LV maximal wall thickness in homozygous/compound 
heterozygous individuals, compared with their heterozygous or 
wild- type family members. After segregation analysis in the fami-
lies, a combined LOD score of 4.25 was obtained, which is indic-
ative of strong cosegregation (online supplementary table 4).
Clinical characteristics of homozygous and compound 
heterozygous individuals
The baseline characteristics of all homozygous and compound 
heterozygous individuals after family screening and their 
comparison with wild- type and heterozygous family members 
are shown in table 1.
More detailed clinical, echocardiographic and electro-
cardiographic data on each of the homozygous/compound 
heterozygous are shown in online supplementary table 5. 
The most frequently identified variant in our cohort was 
p.(Gln247*), followed by the p.(Cys23Tyr) variant. The distri-
bution of the identified variants throughout the different func-
tional domains of the protein is shown in figure 2. HCM was 
the most frequent diagnosis (95%), with only one individual 
with biallelic variants in TRIM63 with a different phenotype 
(restrictive cardiomyopathy). The mean age at diagnosis was 
35 years (range 15–69). Forty- five per cent were asymptomatic 
at the first examination, with abnormal ECG being the most 
frequent cause of diagnosis (25%). Fifty per cent of patients 
with available information had concentric left ventricular 
hypertrophy (LVH), and none had LV outflow tract obstruc-
tion. The mean maximal LV wall thickness was 19 mm (±5). 
At the moment of inclusion, no patient had extreme LV hyper-
trophy (ie, >30 mm); however, one patient with a maximal LV 
wall thickness of 17 mm showed significant wall thinning, with 
a previously reported septal wall thickness of 33 mm (without 
septal reduction therapies). Significant degrees of late gado-
linium enhancement (LGE) (ie, transmural and involving more 
than one myocardial segment) were observed in almost 80% of 
homozygous/compound heterozygous and 20% of our popula-
tion progressed to LV systolic dysfunction (defined as LV ejec-
tion fraction (LVEF) <50%). All patients with LV dysfunction 
showed LGE on MRI studies. Figure 3 shows two examples 
of patients’ cardiac MRIs. Fifty per cent of the patients had 
non- sustained ventricular tachycardia on Holter monitoring. 
One patient had hemodynamically stable sustained ventric-
ular tachycardia, which prompted the implantation of an 
implantable cardioverter defibrillator for secondary preven-
tion. Twenty per cent of the included individuals underwent a 
formal neurological examination, including muscular imaging 
techniques, and none of them showed evident neuromuscular 
alterations. Only one individual underwent muscle biopsy, 
which was normal. Creatine- kinase leves (CK) levels were 
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wild- type (n=44) P value
Age (range) 33 (15–69) 48 (12–80) 0.002
Hypertension (%) 4/20 (20) 7/44 (16) 0.4
HCM (%) 19/20 (95) 0/44 <0.001
  ASH 8/16 (50)
  Concentric 8/16 (50)
Restrictive 
cardiomyopathy (%)
1/20 (5) 0/44 0.15
Reason for diagnosis (%)
  Syncope 2/20 (10%) N/A N/A
  Angina 2/20 (10%)
  Dyspnoea 3/20 (15%)
  ECG disturbance 5/20 (25%)
  Palpitations 3/20 (15%)
  Family screening 4/20 (20%)
  Others 1/20 (5%)
NYHA functional class 
I–II (%)
19/20 (95) N/A N/A
ECG LVH (%) 13/16 (81) 0/44 <0.001
LVMWT (mm) 19.2 (±5.6) 9.8 (±1.9) <0.001
LVMWT>25 mm (%) 3/20 (15) 0/44 <0.001
PW (mm) 13.6 (±3) 8.8 (±2) 0.01
LVEDD (mm) 49.4 (±7.5) 45.4 (±4.8) 0.02
LVEF (%) 60 (±12) 63.4 (±3.7) <0.001
LV dysfunction
(EF<50%) (%)
4/20 (20) 0/44 0.003
LA diameter (mm) 43 (±5) 32 (±5) 0.7
LVOTO 0/20 N/A N/A
CMR LGE (%) 10/12 (83) N/A N/A
Atrial fibrillation (%) 3/20 (15) 0/40 0.012
NSVT on Holter (%) 9/18 (50) N/A N/A
ICD implant (%) 7/20 (35) N/A   N/A
Betablockers (%) 12/20 (60) N/A N/A
Oral anticoagulants (%) 5/20 (25) 0/44 <0.001
Events
  Cardiovascular death 0/20
  CVE 4/20 1/44
  Heart failure death/
heart transplant
0/20
  SCD 0/20
ASH, asymmetric septal hypertrophy; CMR, cardiac magnetic resonance; CVE, 
cerebrovascular event; ECG, electrocardiogram; HCM, hypertrophic cardiomyopathy; ICD, 
implantable cardioverter defibrillator; LA, left atrium; LVEDD, left ventricular end- diastolic 
diameter; LVEF, left ventricular ejection fraction; LVH, left ventricular hypertrophy; LVMWT, 
left ventricular maximal wall thickness; LVOTO, left ventricular outflow tract obstruction; 
NSVT, non- sustained ventricular tachycardia; NYHA, New York Heart Association; PW, 
posterior wall; SCD, sudden cardiac death.
elevated in 3 out of 11 evaluated patients. None of the evalu-
ated cases had previous episodes of sudden cardiac death. Four 
patients (20%) had a previous cerebrovascular event, none of 
them disabling.
dIsCussIOn
Our study demonstrates a relationship between homozygous 
and compound heterozygous rare variants in TRIM63 and the 
development of HCM. Autosomal- recessive (AR) inheritance 
has been considered the least common form of inheritance 
in inherited cardiac muscle diseases and is mainly associated 
with metabolic or complex multi- system disorders.13 14 More 
than 11 600 probands with different cardiovascular inherited 
disorders were sequenced, and rare homozygous and compound 
heterozygous variants in TRIM63 were identified only in subjects 
with HCM (and one case with RCM), whereas they were absent 
in our control population. Likewise, homozygous individuals 
harbouring rare variants in TRIM63 are absent in the gnomAD 
database. Moreover, familial evaluation confirmed these find-
ings, as heterozygous carriers were healthy and only homozygous 
and compound heterozygous individuals showed manifestations 
of the disease. Even though two family members (homozygous) 
did not fulfil the classical criteria for HCM, we classified them 
as possibly affected on the basis of an abnormal ECG (online 
supplementary figure 2). It has been described that ECG changes 
in the absence of diagnostic morphological abnormalities (in 
the context of a familial disease) may represent an early or mild 
form of HCM.13
Sarcomeric proteins undergo constant turnover in order to 
adapt to the physiological needs as well as to repair damaged 
proteins.4 Central to this turnover is the ubiquitin proteasome 
system (UPS). E3 ubiquitin ligases direct the addition of ubiq-
uitin to specific target proteins, marking them for degradation.15 
Substrates targeted by MuRF1 include several members of the 
contractile apparatus, such as myosin heavy chain, troponins, 
tropomyosin and titin.6 16 17 Online supplementary figure 3 
shows a schematic representation of the role of ubiquitin ligases 
in the UPS. Due to its interactions with sarcomeric proteins, 
TRIM63, encoding MuRF1, has been proposed as a candidate 
gene for the development of cardiomyopathies. However, most 
descriptions focused on heterozygous carriers or isolated homo-
zygous individuals without familial cosegregation studies,8 18 and 
its true relevance as a cardiomyopathy- causing gene has not yet 
been elucidated.
One previous study19 reported a family in which a male 
harbouring the p.(Gln247*) variant in TRIM63 in homozygosity 
and the heterozygous missense TRIM54 variant p.(Asp106Asn) 
had HCM and skeletal myopathy. His siblings heterozygous for 
the TRIM63 variant were asymptomatic and healthy. One of his 
sisters was also a homozygous for the p.(Gln247*) variant, but 
not a carrier of the TRIM54 variant, and was diagnosed with 
LV hypertrophy thought to be secondary to hypertension. This 
group reported that the presence of digenic mutations (TRIM63 
and TRIM54) would be necessary for the development of the 
phenotype and that the homozygous TRIM63 variant would 
deserve further investigation in order to establish its contribu-
tion to the development of LV hypertrophy.
The presence of concentric hypertrophy is not a frequent 
presentation in sarcomeric HCM and may be more common 
in metabolic and infiltrative disorders.13 However, 50% of the 
patients with HCM included in our study showed this distribu-
tion. The finding of concentric HCM together with extensive 
LGE distribution prompted the search for an infiltrative disease 
in three of our patients (15%), and was ruled out in all of them. 
The clinical suspicion of infiltrative disorder together with the 
presence of extensive LGE and LV systolic dysfunction in our 
population matches the description of the cardiac phenotype in 
the proband reported by Olivé et al.19
End- stage HCM (defined as EF <50%) has been identified in 
up to 10% of individuals with HCM in modern cohorts, and it 
has been suggested that the progression to this phenotype may 
be lower in individuals with sarcomeric HCM when compared 
with phenocopies.1 20–22 Nevertheless, in our study, 20% of indi-
viduals showed progression to LV dysfunction. Moreover, in one 
family, there was also a history of heart transplant due to end- 
stage HCM in an individual with unknown genotype. Animal 
studies have shown an increase in myocardial fibrosis in mice 
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Key messages
What is already known on this subject?
 ► Up to 50% of patients with hypertrophic cardiomyopathy 
(HCM) show no disease- causing variants in genetic studies. 
TRIM63 has been suggested as a candidate gene for the 
development of cardiomyopathies, although evidence for a 
causative role in HCM is limited.
What might this study add?
 ► This study adds to the genetic architecture of HCM by 
showing that TRIM63 is a cause of a non- classical form of 
HCM, with an autosomal- recessive inheritance, presenting 
as concentric HCM with a high rate of left ventricular (LV) 
dysfunction.
How might this impact on clinical practice?
 ► Our findings have a relevant impact on the genetic 
counselling of these families, as all the available evidence 
suggests that TRIM63 is a cause of HCM only with 
autosomal- recessive inheritance. Moreover, the clinical profile 
of these patients (moderate to severe hypertrophy, high 
incidence of ventricular arrhythmias, extensive fibrosis and 
frequent LV systolic dysfunction) suggests that homozygous 
and compound heterozygous individuals for variants in 
TRIM63 are at high risk of adverse events.
Figure 2 Schematic representation of the protein’s domains. Location of the identified homozygous/compound heterozygous variants in TRIM63 at 
protein level.
Figure 3 Cardiac MRI. Panels A and B show patient II.3 from family 
6897. Severe concentric LV hypertrophy (20 mm IVS) and severe 
transmural LGE were observed. Panels C and D show patient II.2 from 
family 2523, who developed LV systolic dysfunction and dilatation. 
Severe transmural LGE is observed in the apical segments and near- 
transmural LGE in the interventricular septum. Hypertrabeculation of the 
lateroapical segments was found. LGE, late gadolinium enhancement; 
LV, left ventricular.
harbouring mutations in TRIM63, and myocardial fibrosis has 
been shown to be a key determinant of LV adverse remodelling 
in other cardiomyopathies.23–25
Interestingly, the previously described variant p.(Gln247*) 
was the most frequently identified variant in our cohort. Func-
tional studies have shown that this variant reduces the localisa-
tion of the protein to the Z- disk and impairs the ubiquitination 
of MuRF1 substrates in cardiac myocytes.8 RT- PCR analysis 
suggested that the transcripts undergo nonsense- mediated 
decay (a mechanism responsible for haploinsufficiency); more-
over, transient expression of wild- type MuRF1 rescued the 
phenotype in adult human myocytes.19 Sixty per cent of the 
identified missense variants in our cohort are located in the 
RING domain, a highly conserved region (see figure 2 and 
online supplementary figure 4) which mediates ubiquitination 
events.26 Other groups8 have shown that missense variants 
located in the RING domain can significantly decrease the 
enzyme’s autoubiquitination function and the ubiquitination 
of the substrates, as well as producing an activation in the 
mTOR pathway signalling (important for the development of 
ventricular hypertrophy). Furthermore, three out of five (60%) 
of all the missense variants identified involve the substitution 
of cysteine (a neutral polar side chain amino acid) for tyro-
sine (an aromatic hydrophobic side chain amino acid), which 
causes very significant changes in the physicochemical prop-
erties and may alter the structure and function of the protein.
Although our findings will affect a small subset of patients 
with HCM, they are important in clinical practice because they 
have a relevant impact on the genetic counselling of these fami-
lies, as all the available evidence suggests that TRIM63 is a cause 
of HCM with AR inheritance. Moreover, the clinical profile of 
these patients (moderate to severe hypertrophy, high incidence 
of ventricular arrhythmias, extensive fibrosis and frequent LV 
systolic dysfunction) suggests that individuals homozygous and 
compound heterozygous for variants in TRIM63 are at high 
risk of adverse events. The absence of arrhythmic events in our 
cohort may be due to a lack of long- term follow- up of the iden-
tified carriers.
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study limitations
The fact that no other TRIM protein family members have 
been studied in our cohort made it impossible to study whether 
digenic variants could explain the development of clinical myop-
athy or elevated CK observed in some patients.
COnCLusIOn
TRIM63 is a cause of HCM with an AR inheritance pattern, 
which may be associated with concentric LVH and a high rate 
of LV dysfunction. It accounts for approximately 0.4% of HCM 
cases, although its importance in sporadic cases could be higher. 
If these findings are validated by other groups, it is possible that 
TRIM63 is the most frequent cause of HCM with a recessive 
inheritance pattern.
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